[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100442519":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":34,"centralContacts":38,"locations":39,"responsibleParty":52,"collaborators":38,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":38,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":38,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":38,"overallStatus":73,"whyStopped":38,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Sanofi","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"efanesoctocog alfa (BIVV001)","EXPERIMENTAL","Each participant will be sequentially dosed with three single intravenous (IV) doses of first rFVIII (Advate®), second Polyethylene Glycol (PEG)-rFVIII (Adynovi® or Adynovate®), and lastly, BIVV001",[13,14,15],"Drug: Efanesoctocog alfa","Drug: Octocog alfa","Drug: Rurioctocog alfa pegol",[17,24,29],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":22},"DRUG","Efanesoctocog alfa","Solution for injection Intravenous",[9],[23],"BIVV001",{"type":18,"name":25,"description":20,"armGroupLabels":26,"otherNames":27},"Octocog alfa",[9],[28],"Advate®",{"type":18,"name":30,"description":20,"armGroupLabels":31,"otherNames":32},"Rurioctocog alfa pegol",[9],[33],"Adynovi®",[35],{"name":36,"affiliation":5,"role":37},"Clinical Sciences and Operations","STUDY_DIRECTOR",null,[40],{"facility":41,"status":38,"city":42,"state":38,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":38},"Investigational Site Number :1000001","Sofia","1756","Bulgaria","BG",{"type":47,"coordinates":48},"Point",[49,50],23.32415,42.69751,{"lat":50,"lon":49},{"type":53,"investigatorFullName":38,"investigatorTitle":38,"investigatorAffiliation":38,"oldNameTitle":38,"oldOrganization":38},"SPONSOR","100442519","phase-1-pharmacokinetic-assessment-of-standard-half-life-shl-fviii-extended-half-life-ehl-fviii-and-efanesoctocog-alfa-bivv001-in-severe-hemophilia-a-100442519",false,"NCT05042440","Pharmacokinetic Assessment of Standard Half-Life (SHL) FVIII, Extended Half-Life (EHL) FVIII, and Efanesoctocog Alfa (BIVV001) in Severe Hemophilia A","A Phase 1, Single-Site, Open-Label Study to Assess Pharmacokinetics of Efanesoctocog Alfa (BIVV001), Standard Half-Life and Extended Half-Life FVIII After Each Single Intravenous Injection in a Fixed Sequence, in Previously Treated Adults With Severe Hemophilia A","Inclusion Criteria:\n\n* Severe hemophilia A, defined as \\\u003C1 IU\u002FdL (\\\u003C1%) endogenous FVIII activity.\n* Previous treatment for hemophilia A, defined as at least 150 days documented prior exposure to any recombinant and\u002For plasma-derived FVIII and\u002For cryoprecipitate products at Day 1.\n* Platelet count ≥100,000 cells\u002FµL at Screening.\n* A participant known to be human immunodeficiency virus (HIV) antibody positive, either previously documented or identified from screening assessments, must have the following results prior to enrollment. (CD4 lymphocyte count \\>200 cells\u002Fmm³ - Viral load of \\\u003C400 copies\u002FmL).\n\nExclusion Criteria:\n\n* Any concurrent clinically significant liver disease that, in the opinion of the Investigator, would make the participant unsuitable for enrollment. This may include, but is not limited to cirrhosis, portal hypertension, and acute hepatitis.\n* Serious active bacterial, fungal or viral infection (other than chronic hepatitis or HIV) present within 30 days of Screening.\n* Other known coagulation disorder(s) in addition to hemophilia A.\n* History of hypersensitivity or anaphylaxis associated with any FVIII product.\n* History of a positive inhibitor test defined as ≥0.6 BU\u002FmL, or any value greater than or equal to the lower sensitivity cut-off for laboratories with cut-offs for inhibitor detection between 0.7 and 1.0 BU\u002FmL, or clinical signs or symptoms of decreased response to FVIII administrations. Family history of inhibitors will not exclude the participant.\n* Positive inhibitor result, defined as ≥0.6 BU\u002FmL at Screening.\n* Major surgery within 8 weeks of Screening.\n* Sensitivity to any of the study interventions, or components thereof, or drug or other allergy.\n\nThe above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.","MALE","18 Years","65 Years",{"count":65,"type":66},13,"ACTUAL","INTERVENTIONAL",[69],"PHASE1","Primary objective\n\n• To assess the half-life of BIVV001, Standard Half-Life (SHL) rFVIII and Extended Half-Life (EHL) rFVIII after a single intravenous (IV) injection\n\nSecondary objectives\n\n* To characterize additional pharmacokinetic (PK) parameters of BIVV001, SHL rFVIII and EHL rFVIII after a single IV injection\n* To evaluate the safety and tolerability of a single IV injection of BIVV001",[72],"Hemophilia A","COMPLETED","2025-09-12",{"date":76,"type":66},"2025-09-18",{"date":78,"type":66},"2021-08-11",{"date":80,"type":66},"2021-11-24",{"name":5,"class":6},1]